Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ULC004
MIFTS: 72

Ulcerative Colitis

Categories: Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ulcerative Colitis

About this section

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis 38 12 76 25 37 43 3 15 73
Inflammatory Bowel Disease, Ulcerative Colitis Type 25
Chronic Left-Sided Ulcerative Colitis 73
Left-Sided Ulcerative Colitis 12
Left Sided Ulcerative Colitis 73
Idiopathic Proctocolitis 25
Colitis, Ulcerative 44
Colitis Ulcerative 55
Colitis Gravis 25
Uc 25

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Ulcerative Colitis

About this section
MedlinePlus : 43 Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ulcerative Colitis, also known as inflammatory bowel disease, ulcerative colitis type, is related to inflammatory bowel disease and colitis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Ulcerative Colitis is MIR192 (MicroRNA 192
Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues. In situ hybridization analysis indicated that miR-192, an miRNA with decreased expression in active UC, was predominantly localized to colonic epithelial cells. Macrophage inflammatory peptide (MIP)-2 alpha, a chemokine expressed by epithelial cells, was identified as a target of miR-192. In colon epithelial cells, induction of MIP-2 alpha expression by tumor necrosis factor-alpha was accompanied by a concomitant reduction in miR-192 expression and miR-192 was observed to regulate the expression of MIP-2 alpha. CONCLUSIONS: These findings expand the known roles of miRNAs, indicating that tissues from patients with UC, and possibly other chronic inflammatory diseases, have altered miRNA expression patterns. These findings also demonstrate that miRNAs regulate colonic epithelial cell-derived chemokine expression. ), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and Jak-STAT signaling pathway. The drugs Azathioprine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and colon, and related phenotype is digestive/alimentary.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

Genetics Home Reference : 25 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.

Disease Ontology : 12 A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Wikipedia : 76 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Sources

Related Diseases for Ulcerative Colitis

About this section

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 455)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 32.8 ABCB1 ATG16L1 IL23R MPO MUC2 NOD2
2 colitis 32.2 ABCB1 ATG16L1 IL23R MLH1 MPO MUC2
3 crohn's disease 32.1 ABCB1 ATG16L1 IL23R MUC2 NOD2 TNF
4 ileitis 31.3 MPO NOD2 TNF
5 granulomatous dermatitis 31.3 NOD2 TNF
6 spondylitis 31.1 IL23R NOD2 TNF
7 autoimmune inner ear disease 30.8 MPO TNF
8 ileocolitis 30.7 NOD2 TNF
9 anca-associated vasculitis 30.4 MPO TNF
10 gastrointestinal system disease 30.4 ATG16L1 MPO NOD2 TNF
11 psoriatic arthritis 29.6 IL23R NOD2 TNF
12 kidney cancer 29.4 H19 MIR126 MIR21 MIR29A
13 gastric cancer 28.0 H19 MIR192 MIR203A MIR21 MLH1 MUC2
14 colorectal cancer 27.9 ABCB1 H19 MIR126 MIR192 MIR195 MIR203A
15 systemic lupus erythematosus 27.9 MIR195 MIR23A MIR629 MPO TNF
16 esophageal cancer 27.3 FOXD2-AS1 H19 MIR126 MIR192 MIR203A MIR21
17 hepatocellular carcinoma 25.0 H19 MIR126 MIR195 MIR203A MIR21 MIR23A
18 pediatric ulcerative colitis 12.3
19 inflammatory bowel disease 1 11.8
20 ulcerative proctitis 11.5
21 irritable bowel syndrome 11.5
22 pouchitis 11.4
23 pyoderma gangrenosum 11.4
24 bile duct carcinoma 11.3
25 colonic disease 11.3
26 polyposis syndrome, hereditary mixed, 1 11.3
27 inflammatory bowel disease 10 11.1
28 inflammatory bowel disease 13 11.1
29 inflammatory bowel disease 14 11.1
30 inflammatory bowel disease 17 11.1
31 inflammatory bowel disease 19 11.1
32 inflammatory bowel disease 25, autosomal recessive 11.1
33 inflammatory bowel disease 28, autosomal recessive 11.1
34 colorectal cancer 1 11.0
35 colorectal cancer 3 11.0
36 colorectal cancer 10 11.0
37 autoimmune disease 6 11.0
38 colorectal cancer 12 11.0
39 fecal incontinence 11.0
40 chemical colitis 11.0
41 inflammatory bowel disease 9 10.9 MLH1 NOD2
42 myelodysplastic myeloproliferative cancer 10.9
43 inflammatory bowel disease 5 10.9 ATG16L1 IL23R NOD2
44 microscopic polyangiitis 10.9 MPO TNF
45 ovarian mucinous adenocarcinoma 10.8 ABCB1 MUC2
46 suppurative cholangitis 10.8 MPO MUC2 TNF
47 idiopathic achalasia 10.7 IL23R TNF
48 mucositis 10.6
49 sclerosing cholangitis 10.6
50 cholangitis 10.6

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis
Sources

Symptoms & Phenotypes for Ulcerative Colitis

About this section

UMLS symptoms related to Ulcerative Colitis:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Ulcerative Colitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 ABCB1 ATG16L1 IL23R MLH1 MUC2 NOD2
Sources

Drugs & Therapeutics for Ulcerative Colitis

About this section

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
6
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
7
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
8
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
9 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 943609-66-3
10
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
12
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
14
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
15
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
16
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
17
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
18
Nicotine Approved Phase 4 54-11-5 942 89594
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
20
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
21
Methotrexate Approved Phase 4,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
22
Vancomycin Approved Phase 4,Phase 1,Not Applicable 1404-90-6 441141 14969
23
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
24
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
25
Losartan Approved Phase 4 114798-26-4 3961
26
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
27
Copper Approved, Investigational Phase 4 7440-50-8 27099
28
Zinc Approved, Investigational Phase 4 7440-66-6 23994
29
Thioguanine Approved Phase 4 154-42-7 2723601
30
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
31
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
32 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Not Applicable
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 59-30-3 6037
34
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 58-05-9 143 6006
35
Vitamin C Approved, Nutraceutical Phase 4,Not Applicable 50-81-7 5785 54670067
36
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
37
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 2 1406-66-2 14986
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-02-9 14985
39
Butyric Acid Experimental, Investigational Phase 4,Phase 2,Not Applicable 107-92-6 264
40 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
42 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 6-Mercaptopurine Phase 4,Phase 3,Phase 2,Not Applicable
44 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
47 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Not Applicable
48 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
49 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 944)
# Name Status NCT ID Phase Drugs
1 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
2 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
3 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
4 A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis Unknown status NCT02425852 Phase 4 Azathioprine;Infliximab;Prednisolone;Hydrocortisone
5 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
6 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
7 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
8 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
9 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4 VSL#3
10 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
11 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
12 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
13 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
14 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
15 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
16 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
17 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
18 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
19 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
20 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
21 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
22 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
23 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
24 Correlation of Soluble ST2 With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
25 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
26 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
27 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
28 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
29 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
30 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
31 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
32 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
33 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
34 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
35 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
36 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
37 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
38 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
39 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4 Antibiotic cocktail
40 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4 Infliximab
41 Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients Recruiting NCT03581149 Phase 4 Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
42 Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis Recruiting NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
43 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Recruiting NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
44 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Recruiting NCT02998112 Phase 4 fecal microbiota transplantation;Saline
45 An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis Recruiting NCT03237260 Phase 4 Vedolizumab
46 Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease Recruiting NCT02743806 Phase 4 Vedolizumab
47 Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis Recruiting NCT03151525 Phase 4 Azathioprine;Infliximab
48 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Recruiting NCT03029143 Phase 4 Vedolizumab IV
49 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
50 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Recruiting NCT02559713 Phase 4 Vedolizumab

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Ulcerative Colitis:
MultiStem
Regenerative ColoTherapy
Embryonic/Adult Cultured Cells Related to Ulcerative Colitis:
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285
Adipose-derived mesenchymal stem cells (family)
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: colitis, ulcerative

Sources

Genetic Tests for Ulcerative Colitis

About this section
Sources

Anatomical Context for Ulcerative Colitis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Ulcerative Colitis:

19
Colon

MalaCards organs/tissues related to Ulcerative Colitis:

41
Colon, Testes, T Cells, Liver, Bone, Neutrophil, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
Sources

Publications for Ulcerative Colitis

About this section

Articles related to Ulcerative Colitis:

(show top 50) (show all 2748)
# Title Authors Year
1
A Case of Pulmonary Alveolar Proteinosis with Ulcerative Colitis. ( 29709938 )
2018
2
5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. ( 29951050 )
2018
3
Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. ( 29435325 )
2018
4
Long-Term Outcomes of Immunosuppression-NaA^ve Steroid Responders Following Hospitalization for Ulcerative Colitis. ( 29951797 )
2018
5
Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. ( 29450747 )
2018
6
The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. ( 29968483 )
2018
7
Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-I_B/MAPKs Pathway. ( 29959727 )
2018
8
The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis. ( 29941222 )
2018
9
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. ( 29928204 )
2018
10
Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis. ( 29607962 )
2018
11
Fresh Fruit Juice of Opuntia dillenii Haw. Attenuates Acetic Acid-Induced Ulcerative Colitis in Rats. ( 29958056 )
2018
12
Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. ( 29424814 )
2018
13
Pyoderma Gangrenosum of the Preauricular Area with Ulcerative Colitis: A Case Report and Review. ( 29890815 )
2018
14
What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab? ( 29668955 )
2018
15
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
16
An Overview of Molecular Profiles in Ulcerative Colitis-Related Cancer. ( 29945208 )
2018
17
Ileal pouch of ulcerative colitis and familial adenomatous polyposis patients exhibit modulation of autophagy markers. ( 29422639 )
2018
18
Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue. ( 29401083 )
2018
19
High Incidence of Recurrent Crohn's Disease Following Colectomy for Ulcerative Colitis Revealed with Long Follow-Up. ( 29282640 )
2018
20
Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis. ( 29541900 )
2018
21
A case of pemphigus vulgaris associated with ulcerative colitis. ( 29422810 )
2018
22
Case of pyoderma gangrenosum-like sporotrichosis caused by Sporothrix globosa in a patient with ulcerative colitis. ( 29488248 )
2018
23
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. ( 29850873 )
2018
24
Ulcerative colitis followed by the development of typical intestinal BehAset disease: A case report. ( 29443756 )
2018
25
Ulcerative colitis with Guillain-BarrAc syndrome: A case report. ( 29923987 )
2018
26
Ulcerative colitis: yet another paradoxical effect of tumour necrosis factor blockers? ( 29441549 )
2018
27
EBV colitis with ulcerative colitis: a double whammy. ( 29960963 )
2018
28
Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis. ( 29767352 )
2018
29
MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor I+-1. ( 29438285 )
2018
30
Management of iatrogenic perforation during colonoscopy in ulcerative colitis patients: a survey of gastroenterologists and colorectal surgeons. ( 29978362 )
2018
31
Altered Salivary Alpha-Amylase Secretion in Patients with Ulcerative Colitis. ( 29977288 )
2018
32
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. ( 29946178 )
2018
33
Duodenal amyloidosis secondary to ulcerative colitis. ( 29422811 )
2018
34
Introducing Traditional Herbal Medicine into Conventional Health Care in Treating Ulcerative Colitis: Primum Non Nocere. ( 29425926 )
2018
35
Partial to complete abrogation of the subepithelial macrophage barrier against the gut microbiota in patients with ulcerative colitis and Crohn's colitis. ( 29023984 )
2018
36
>0 g, a8o5 g A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. ( 29977035 )
2018
37
Gastrointestinal: Ulcerative colitis-associated duodenitis. ( 29659081 )
2018
38
Medical and Surgical Management of Pediatric Ulcerative Colitis. ( 29487489 )
2018
39
The Complexity of Renal Involvment in IBD-C3 Glomerulopathy in Ulcerative Colitis. ( 29522131 )
2018
40
Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. ( 29361101 )
2018
41
Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature. ( 29546806 )
2018
42
Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threating Life Complication. ( 29931191 )
2018
43
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis. ( 29981298 )
2018
44
Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis. ( 29422812 )
2018
45
Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. ( 29427297 )
2018
46
Novel score predicts risk for cytomegalovirus infection in ulcerative colitis. ( 29940421 )
2018
47
Mesalazine-induced Bronchiolitis Obliterans with Organizing Pneumonia in a young patient with Ulcerative Colitis. ( 29931114 )
2018
48
The possible relationship between Campylobacter spp./Arcobacter spp. and patients with ulcerative colitis. ( 29432367 )
2018
49
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. ( 29969780 )
2018
50
A data-based hypothesis explicating the observations that "Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study". ( 29447017 )
2018
Sources

Variations for Ulcerative Colitis

About this section
Sources

Expression for Ulcerative Colitis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating islet-derived 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 (anion exchanger), member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.13 0.000
6 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.86 0.003
7 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 3.85 0.000
8 REG1A regenerating islet-derived 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G-protein signaling 3 Colon + 3.58 0.000
10 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.
Sources

Pathways for Ulcerative Colitis

About this section

Pathways related to Ulcerative Colitis according to KEGG:

37
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 Jak-STAT signaling pathway hsa04630
3 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 37
11.75 ABCB1 MIR126 MIR192 MIR195 MIR203A MIR21
2
miRNAs involved in DNA damage response 1
10.83 MIR203A MIR23A MIR23B
3
Canonical NF-kappaB pathway 1
10.73 NOD2 TNF
4
LDL Oxidation in Atherogenesis 64
10.53 MPO TNF
5
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 61
10.43 ABCB1 MPO
6
EV release from cardiac cells and their functional effects 1
10.11 MIR126 TNF
Sources

GO Terms for Ulcerative Colitis

About this section

Cellular components related to Ulcerative Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MIR126 MIR192 MIR21 MIR23A MIR23B MIR29A

Biological processes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 MIR126 MIR21 NOD2 TNF
2 negative regulation of gene expression GO:0010629 9.71 MIR21 MIR23B MIR29A TNF
3 positive regulation of protein kinase B signaling GO:0051897 9.56 MIR126 MIR21 MIR29A TNF
4 positive regulation of osteoclast differentiation GO:0045672 9.52 IL23R TNF
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.51 MIR21 NOD2
6 negative regulation of growth of symbiont in host GO:0044130 9.49 MPO TNF
7 positive regulation of interleukin-17 production GO:0032740 9.48 IL23R NOD2
8 maintenance of gastrointestinal epithelium GO:0030277 9.46 MUC2 NOD2
9 positive regulation of T-helper 17 type immune response GO:2000318 9.37 IL23R MIR21
10 gene silencing by miRNA GO:0035195 9.35 MIR126 MIR21 MIR23A MIR23B MIR29A
11 positive regulation of vascular endothelial cell proliferation GO:1905564 9.33 MIR126 MIR21 MIR29A
12 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.32 MIR21 TNF
13 cell growth involved in cardiac muscle cell development GO:0061049 8.8 MIR195 MIR23A MIR23B

Molecular functions related to Ulcerative Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR126 MIR21 MIR23A MIR23B MIR29A
Sources

Sources for Ulcerative Colitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....